Marc Lohrmann is the Managing Partner of Vesalius Biocapital III. See sector focus and contact routes.
Marc Lohrmann is the Managing Partner of Vesalius Biocapital III, a role he assumed in 2017 after joining the firm in 2012 as a venture partner, bringing over 20 years of life sciences experience including co-founding Reverse Medical and working at Bayer Innovation. His firm’s investment thesis targets late-stage companies in drug development, medical devices, diagnostics, and eHealth/mHealth across all of Europe. Typical check sizes are not explicitly detailed in available sources, though the fund itself is a €120 million venture capital vehicle focused on these sectors. Notable portfolio companies include DEARhealth, an AI-powered chronic care spin-out from UCLA; Forendo Pharma, a clinical-stage women’s health drug developer; and SWORD Health, a digital musculoskeletal therapy provider backed by Khosla Ventures and Founders Fund. Lohrmann has publicly discussed “life sciences returns and complexity” in a video presentation, highlighting the nuanced challenges of the sector. He also joined KELES as an Investment Partner in March 2025, leading operations in the German-speaking region while maintaining his Vesalius role.
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Munich.
Investors like Marc Lohrmann · Full investor directory · Investor access · Company funding database